OryKL-delivered scFv αIIbβ3 self-amplifying mRNA provided sustained thromboprotection for over 7 days in a murine thrombosis model without increasing bleeding times or systemic toxicity.
Does scFv αIIbβ3-encoding mRNA prevent thrombus formation without increasing bleeding risk in a murine arterial thrombosis model?
A novel self-amplifying mRNA therapeutic encoding a platelet-targeted scFv provides prolonged thromboprophylaxis without increasing bleeding risk in a preclinical murine model.
BACKGROUND: Thrombosis is a major contributor to morbidity and mortality in cardiovascular diseases. Although current antiplatelet therapies reduce thrombotic complications, they are associated with systemic bleeding complications. We previously developed a single-chain variable fragment (scFv) that specifically binds and blocks the activated platelet integrin αIIbβ3 (GPIIb/IIIa glycoprotein IIb/IIIa), preventing thrombosis without impairing hemostasis. We hypothesized that an mRNA-based therapeutic encoding scFv αIIbβ3 would offer prolonged expression and enhanced therapeutic durability while maintaining a favorable safety profile. METHODS: We designed and synthesized both conventional mRNA and self-amplifying mRNA constructs encoding scFv αIIbβ3 . The constructs were first validated in vitro by confirming their expression of a functional scFv αIIbβ3 . For in vivo experiments, mRNAs were encapsulated in a novel lipid nanoparticle formulation comprising of γ-oryzanol and DLin-KC2-DMA (OryKL) for systemic delivery. Their biosafety was assessed by a series of biochemical and histological examinations. The murine FeCl 3 -induced arterial thrombosis model was used to assess the preventive effect of scFv αIIbβ3 -encoding mRNAs on thrombus formation. RESULTS: In vitro assays confirmed the efficient expression and secretion of a functional scFv αIIbβ3 that selectively bound to and blocked activated GPIIb/IIIa, thereby inhibited platelet aggregation. In mice with induced thrombosis, OryKL-delivered scFv αIIbβ3 mRNA significantly prolonged occlusion time at 24 hours posttreatment, while self-amplifying mRNA provided sustained thromboprotection for over 7 days. Tail bleeding times were unchanged across all groups, and no systemic toxicity or histopathologic abnormalities were observed. CONCLUSIONS: Our findings demonstrate that scFv αIIbβ3 mRNA and self-amplifying mRNA therapeutics enable safe, effective, and long-acting antithrombotic protection in vivo, offering a promising strategy for thromboprophylaxis that prevents the bleeding risks associated with current antiplatelet therapies.
Song et al. (Mon,) conducted a other in Thrombosis. scFv αIIbβ3 mRNA and self-amplifying mRNA was evaluated on Occlusion time and tail bleeding time. OryKL-delivered scFv αIIbβ3 self-amplifying mRNA provided sustained thromboprotection for over 7 days in a murine thrombosis model without increasing bleeding times or systemic toxicity.